Browse HOXC11

Summary
SymbolHOXC11
Namehomeobox C11
Aliases HOX3H; homeo box C11; homeobox protein Hox-3H; Homeobox protein Hox-C11
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus.
Domain PF12045 Protein of unknown function (DUF3528)
PF00046 Homeobox domain
Function

Sequence-specific transcription factor which is part of a developmental regulatory system that provides cells with specific positional identities on the anterior-posterior axis. Binds to a promoter element of the lactase-phlorizin hydrolase gene.

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0001655 urogenital system development
GO:0001656 metanephros development
GO:0001759 organ induction
GO:0001822 kidney development
GO:0003002 regionalization
GO:0003156 regulation of animal organ formation
GO:0007389 pattern specification process
GO:0007492 endoderm development
GO:0009952 anterior/posterior pattern specification
GO:0009954 proximal/distal pattern formation
GO:0010092 specification of animal organ identity
GO:0030326 embryonic limb morphogenesis
GO:0031128 developmental induction
GO:0035107 appendage morphogenesis
GO:0035108 limb morphogenesis
GO:0035113 embryonic appendage morphogenesis
GO:0042733 embryonic digit morphogenesis
GO:0048562 embryonic organ morphogenesis
GO:0048568 embryonic organ development
GO:0048645 animal organ formation
GO:0048704 embryonic skeletal system morphogenesis
GO:0048705 skeletal system morphogenesis
GO:0048706 embryonic skeletal system development
GO:0048736 appendage development
GO:0060173 limb development
GO:0060272 embryonic skeletal joint morphogenesis
GO:0072001 renal system development
GO:0072498 embryonic skeletal joint development
GO:2000027 regulation of organ morphogenesis
Molecular Function GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001159 core promoter proximal region DNA binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolHOXC11
Namehomeobox C11
Aliases HOX3H; homeo box C11; homeobox protein Hox-3H; Homeobox protein Hox-C11
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between HOXC11 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolHOXC11
Namehomeobox C11
Aliases HOX3H; homeo box C11; homeobox protein Hox-3H; Homeobox protein Hox-C11
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of HOXC11 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.51 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolHOXC11
Namehomeobox C11
Aliases HOX3H; homeo box C11; homeobox protein Hox-3H; Homeobox protein Hox-C11
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of HOXC11 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0450.922
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3430.719
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3370.633
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.1820.234
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.5360.708
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-20.212
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.5910.501
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-1.7960.127
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.1650.407
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0690.915
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.3960.647
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3190.284
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of HOXC11 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolHOXC11
Namehomeobox C11
Aliases HOX3H; homeo box C11; homeobox protein Hox-3H; Homeobox protein Hox-C11
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HOXC11. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolHOXC11
Namehomeobox C11
Aliases HOX3H; homeo box C11; homeobox protein Hox-3H; Homeobox protein Hox-C11
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HOXC11. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HOXC11.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolHOXC11
Namehomeobox C11
Aliases HOX3H; homeo box C11; homeobox protein Hox-3H; Homeobox protein Hox-C11
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HOXC11. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolHOXC11
Namehomeobox C11
Aliases HOX3H; homeo box C11; homeobox protein Hox-3H; Homeobox protein Hox-C11
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of HOXC11 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolHOXC11
Namehomeobox C11
Aliases HOX3H; homeo box C11; homeobox protein Hox-3H; Homeobox protein Hox-C11
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between HOXC11 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolHOXC11
Namehomeobox C11
Aliases HOX3H; homeo box C11; homeobox protein Hox-3H; Homeobox protein Hox-C11
Chromosomal Location12q13.13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting HOXC11 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.